Back to Search
Start Over
Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19
Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19
- Source :
- The Journal of Allergy and Clinical Immunology
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can lead to a variety of clinical outcomes ranging from the absence of symptoms to severe acute respiratory disease and ultimately death. A feature of patients with severe Coronavirus disease 19 (COVID-19) is the abundance of inflammatory cytokines in the blood. Elevated levels of cytokine are predictive of infection severity and clinical outcome. In contrast, studies aimed at defining the driving forces behind the inflammation in lungs of severed COVID-19 subjects remain scarce. Objective To analyze and compare the plasma and bronchoalveolar lavages (BALs) of patients with severe COVID-19 (n=45) for the presence of cytokines and lipid mediators of inflammation (LMI). Methods Cytokines were measured using Luminex multiplex assay and LMI measured using LC-MS/MS. Results We reveal high concentrations of numerous cytokines/chemokines/LMI in BALs of patients with severe COVID-19. Among the 13 most abundant mediators in BALs, 11 were chemokines with CXCL1 and CXCL8 being 200 times more abundant than IL-6 and TNF-α. Eicosanoids were also elevated in lungs of severe COVID-19 subjects. Consistent with the presence chemotactic molecules, BALs were enriched for neutrophils, lymphocytes and eosinophils. Inflammatory cytokines/LMI in plasma showed limited correlations with those present in BALs, arguing that circulating inflammatory molecules may not be a reliable proxy of the inflammation occurring in the lungs of severe COVID-19 patients. Conclusions Our findings indicate that lungs hyperinflammation of severe COVID-19 patients is fueled by excessive production of chemokines and eicosanoids. Therapeutic strategies to dampen inflammation in COVID-19 patients should be tailored accordingly.<br />Graphical abstract
- Subjects :
- Male
0301 basic medicine
ARDS
Chemokine
Neutrophils
inflammatory cytokines
Leukotriene B4
chemokines
030204 cardiovascular system & hematology
Severity of Illness Index
lipid mediators of inflammation
chemistry.chemical_compound
0302 clinical medicine
Immunology and Allergy
Lymphocytes
Lung
medicine.diagnostic_test
biology
Middle Aged
respiratory system
CXCL1
Cytokines
Female
medicine.symptom
Bronchoalveolar Lavage Fluid
Adult
Immunology
Inflammation
macromolecular substances
Article
eicosanoids
Proinflammatory cytokine
03 medical and health sciences
medicine
Humans
Aged
SARS-CoV-2
business.industry
COVID-19
medicine.disease
respiratory tract diseases
030104 developmental biology
Bronchoalveolar lavage
chemistry
Eicosanoid
biology.protein
business
Subjects
Details
- ISSN :
- 00916749
- Volume :
- 148
- Database :
- OpenAIRE
- Journal :
- Journal of Allergy and Clinical Immunology
- Accession number :
- edsair.doi.dedup.....3a8ca295de8f943a62c858c8374b9189
- Full Text :
- https://doi.org/10.1016/j.jaci.2021.05.032